Back to News
Market Impact: 0.2
CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)
Source: Newswire
Healthcare & BiotechCorporate Guidance & Outlook
The company said it remains focused on global development of crofelemer powder for oral solution for microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). It is targeting a mid-2027 NDA filing for MVID; no additional milestones or results were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Marvell, Lumentum tout historic $115B deal to create ‘category leader' in AI connectivity
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Anthropic to Spend $895 Billion in the Years Ahead
- New Apple CEO John Ternus chalks up some early wins, but the honeymoon is over
- Apple Forecast Tops Estimates, Disappoints Investors